The primary patent for daridorexant, known by its brand name Quviviq, is set to expire in 2037 [1]. This patent is listed in the Orange Book [1].
When does the exclusivity for daridorexant end?
Market exclusivity for daridorexant, driven by its primary patent, is anticipated to conclude in 2037 [1].
Can generic versions of daridorexant be available before the patent expires?
Generally, generic versions cannot enter the market before patent expiry unless the patent is successfully challenged or invalidated through litigation [2]. The availability of generics is contingent on patent expiration or the outcome of any legal challenges to the patent's validity [2].
What is daridorexant used for?
Daridorexant is a dual orexin receptor antagonist indicated for the treatment of insomnia [3]. It works by blocking the wake-promoting neurotransmitter orexin [3].
How does daridorexant compare to other insomnia treatments?
Daridorexant's mechanism of action, targeting the orexin system, distinguishes it from other classes of sleep medications such as benzodiazepines or non-benzodiazepine hypnotics, which act on GABA receptors [3][4]. This difference may lead to varied efficacy and side effect profiles [3][4].
What are the potential side effects of daridorexant?
Common side effects reported for daridorexant include somnolence, headache, and fatigue [3]. Patients are advised to avoid driving or engaging in other activities requiring alertness for at least eight hours after taking the medication [3].
Who developed and markets daridorexant?
Daridorexant was developed by Idorsia Pharmaceuticals [5]. It is marketed in the United States by Idorsia Pharmaceuticals US Inc. [3].
What is the regulatory status of daridorexant?
Daridorexant received FDA approval for the treatment of insomnia in January 2022 [3][5]. It is also approved in other regions, including the European Union [5].
Are there ongoing legal challenges to daridorexant patents?
Information regarding specific legal challenges to daridorexant patents is not provided. However, patent challenges are common in the pharmaceutical industry, especially as market exclusivity periods approach [2].
Where can I find more information on drug patents and exclusivity?
For detailed information on drug patents and exclusivity timelines, resources such as DrugPatentWatch.com can be consulted [1].
Sources
- DrugPatentWatch.com
- U.S. Food & Drug Administration (FDA)
- Idorsia Pharmaceuticals US Inc.
- National Institute of Neurological Disorders and Stroke (NINDS)
- European Medicines Agency (EMA)